@bill75331820 @tuduylinh $BLCM failed to deliver so far, even so they have a clinical-successful project (BPX-501, Rivo-Cel) on the shelf that is ready for EU-markets for almost a year. For BPX-601 see this recent market review https://t.co/yVyW2DTVVe
@ChristianHomsy @CelyadSA Well, I posted several reviews over time, included yours, @CelyadSA people, specifically on CAR-Ts in solid tumors, last year. In english, I think I'd have said "the first CAR-T EVER" if I had really meant "the first" as we say in
RT @BertrandBio: Landscape of CAR-Ts in solid tumors by $CYAD: targets, approaches, setting, list of trials... https://t.co/1ZzBrtRLBd http…
Hasta 1/3 de los ensayos con CAR-T se dirigen a neoplasias sólidas, aunque hay todavía quedan dificultades por solventar. #CAR-T https://t.co/aLeXc0vT2M